메뉴 건너뛰기
Annals of Pharmacotherapy
Volumn 50, Issue 6, 2016, Pages 486-501
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Author keywords

apixaban; dabigatran; deep vein thrombosis; direct oral anticoagulants; edoxaban; pulmonary embolism; rivaroxaban; target specific oral anticoagulants; venous thromboembolism
Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;
EID: 84966783522     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016632785     Document Type: Review
Times cited : (20)
References (102)
  • 1
    • 84856784474 scopus 로고    scopus 로고
    • Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • W.AgenoA.S.GallusA.Wittkowsky. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S-e88S.
    • (2012) Chest , vol.141 , pp. e44S-e88S
    • Ageno, W.1    Gallus, A.S.2    Wittkowsky, A.3
  • 2
    • 0037382537 scopus 로고    scopus 로고
    • American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    • J.HirshV.FusterJ.AnsellJ.L.Halperin; American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692-1711.
    • (2003) Circulation , vol.107 , pp. 1692-1711
    • Hirsh, J.1    Fuster, V.2    Ansell, J.3    Halperin, J.L.4
  • 3
    • 84856772158 scopus 로고    scopus 로고
    • Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • A.HolbrookS.SchulmanD.M.Witt. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S-184S.
    • (2012) Chest , vol.141 , pp. e152S-184S
    • Holbrook, A.1    Schulman, S.2    Witt, D.M.3
  • 5
    • 84937521948 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022512s018lbl.pdf. Accessed February 5, 2016.
    • Pradaxa: highlights of prescribing information
  • 6
    • 84937521948 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • Bristol-Myers Squibb Company. Eliquis: highlights of prescribing information. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed February 5, 2016.
    • Eliquis: highlights of prescribing information
  • 7
    • 84937521948 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • Janssen Pharmaceuticals, Inc. Xarelto: Highlights of prescribing information. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed February 5, 2016.
    • Xarelto: Highlights of prescribing information
  • 8
    • 84872124046 scopus 로고    scopus 로고
    • ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients
    • C.E.MahanA.C.SpyropoulosASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health Syst Pharm. 2012;69:2174-2190.
    • (2012) Am J Health Syst Pharm , vol.69 , pp. 2174-2190
    • Mahan, C.E.1    Spyropoulos, A.C.2
  • 9
    • 84966880949 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • Daiichi Sankyo, Inc. SAVAYSA (edoxaban): highlights of prescribing information. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed February 5, 2016.
    • SAVAYSA (edoxaban): highlights of prescribing information
  • 10
    • 84923924319 scopus 로고    scopus 로고
    • Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants
    • N.RivaW.AgenoPros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost. 2015;41:178-187.
    • (2015) Semin Thromb Hemost , vol.41 , pp. 178-187
    • Riva, N.1    Ageno, W.2
  • 11
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • J.StangierK.RathgenH.StähleD.GansserW.RothThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
    • (2007) Br J Clin Pharmacol , vol.64 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stähle, H.3    Gansser, D.4    Roth, W.5
  • 12
    • 25844525489 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    • D.KubitzaM.BeckaB.VoithM.ZuehlsdorfG.WensingSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 412-421
    • Kubitza, D.1    Becka, M.2    Voith, B.3    Zuehlsdorf, M.4    Wensing, G.5
  • 13
    • 84878952383 scopus 로고    scopus 로고
    • Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
    • C.FrostS.NepalJ.Wang. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776-786.
    • (2013) Br J Clin Pharmacol , vol.76 , pp. 776-786
    • Frost, C.1    Nepal, S.2    Wang, J.3
  • 14
    • 84883301339 scopus 로고    scopus 로고
    • The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor
    • J.MendellF.LeeS.ChenV.WorlandM.ShiM.M.SamamaThe effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62:212-221.
    • (2013) J Cardiovasc Pharmacol , vol.62 , pp. 212-221
    • Mendell, J.1    Lee, F.2    Chen, S.3    Worland, V.4    Shi, M.5    Samama, M.M.6
  • 15
    • 79955531668 scopus 로고    scopus 로고
    • Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers
    • J.MendellM.TachibanaM.ShiS.KunitadaEffects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51:687-694.
    • (2011) J Clin Pharmacol , vol.51 , pp. 687-694
    • Mendell, J.1    Tachibana, M.2    Shi, M.3    Kunitada, S.4
  • 16
    • 84872260247 scopus 로고    scopus 로고
    • Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
    • C.FrostJ.WangS.Nepal. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75:476-487.
    • (2013) Br J Clin Pharmacol , vol.75 , pp. 476-487
    • Frost, C.1    Wang, J.2    Nepal, S.3
  • 17
    • 17644400166 scopus 로고    scopus 로고
    • Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
    • J.StangierB.I.ErikssonO.E.Dahl. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563.
    • (2005) J Clin Pharmacol , vol.45 , pp. 555-563
    • Stangier, J.1    Eriksson, B.I.2    Dahl, O.E.3
  • 19
    • 84954367009 scopus 로고    scopus 로고
    • An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics
    • J.MendellL.JohnsonS.ChenAn open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55:1395-1405.
    • (2015) J Clin Pharmacol , vol.55 , pp. 1395-1405
    • Mendell, J.1    Johnson, L.2    Chen, S.3
  • 20
    • 84879486549 scopus 로고    scopus 로고
    • Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
    • D.KubitzaA.RothM.Becka. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76:89-98.
    • (2013) Br J Clin Pharmacol , vol.76 , pp. 89-98
    • Kubitza, D.1    Roth, A.2    Becka, M.3
  • 21
    • 57449098437 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment
    • J.StangierH.StähleK.RathgenW.RothK.Shakeri-NejadPharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48:1411-1419.
    • (2008) J Clin Pharmacol , vol.48 , pp. 1411-1419
    • Stangier, J.1    Stähle, H.2    Rathgen, K.3    Roth, W.4    Shakeri-Nejad, K.5
  • 22
    • 84934323965 scopus 로고    scopus 로고
    • Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment
    • Y.KoretsuneT.YamashitaT.KimuraM.FukuzawaK.AbeM.YasakaShort-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. Circ J. 2015;79:1486-1495.
    • (2015) Circ J , vol.79 , pp. 1486-1495
    • Koretsune, Y.1    Yamashita, T.2    Kimura, T.3    Fukuzawa, M.4    Abe, K.5    Yasaka, M.6
  • 23
    • 84869109465 scopus 로고    scopus 로고
    • Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans
    • M.S.BathalaH.MasumotoT.OgumaL.HeC.LowrieJ.MendellPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250-2255.
    • (2012) Drug Metab Dispos , vol.40 , pp. 2250-2255
    • Bathala, M.S.1    Masumoto, H.2    Oguma, T.3    He, L.4    Lowrie, C.5    Mendell, J.6
  • 24
    • 67650809062 scopus 로고    scopus 로고
    • Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans
    • D.ZhangK.HeN.Raghavan. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37:1738-1748.
    • (2009) Drug Metab Dispos , vol.37 , pp. 1738-1748
    • Zhang, D.1    He, K.2    Raghavan, N.3
  • 25
    • 66449099711 scopus 로고    scopus 로고
    • Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans
    • C.WeinzT.SchwarzD.KubitzaW.MueckD.LangMetabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37:1056-1064.
    • (2009) Drug Metab Dispos , vol.37 , pp. 1056-1064
    • Weinz, C.1    Schwarz, T.2    Kubitza, D.3    Mueck, W.4    Lang, D.5
  • 26
    • 38749131205 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    • S.BlechT.EbnerE.Ludwig-SchwellingerJ.StangierW.RothThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-399.
    • (2008) Drug Metab Dispos , vol.36 , pp. 386-399
    • Blech, S.1    Ebner, T.2    Ludwig-Schwellinger, E.3    Stangier, J.4    Roth, W.5
  • 27
    • 77953787643 scopus 로고    scopus 로고
    • Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers
    • K.OgataJ.Mendell-HararyM.Tachibana. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743-753.
    • (2010) J Clin Pharmacol , vol.50 , pp. 743-753
    • Ogata, K.1    Mendell-Harary, J.2    Tachibana, M.3
  • 28
    • 58149458160 scopus 로고    scopus 로고
    • Apixaban metabolism and pharmacokinetics after oral administration to humans
    • N.RaghavanC.E.FrostZ.Yu. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
    • (2009) Drug Metab Dispos , vol.37 , pp. 74-81
    • Raghavan, N.1    Frost, C.E.2    Yu, Z.3
  • 29
    • 29144518504 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
    • D.KubitzaM.BeckaG.WensingB.VoithM.ZuehlsdorfSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-880.
    • (2005) Eur J Clin Pharmacol , vol.61 , pp. 873-880
    • Kubitza, D.1    Becka, M.2    Wensing, G.3    Voith, B.4    Zuehlsdorf, M.5
  • 30
    • 77949421739 scopus 로고    scopus 로고
    • Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
    • J.StangierK.RathgenH.StähleD.MazurInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-268.
    • (2010) Clin Pharmacokinet , vol.49 , pp. 259-268
    • Stangier, J.1    Rathgen, K.2    Stähle, H.3    Mazur, D.4
  • 31
    • 78649289929 scopus 로고    scopus 로고
    • Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
    • D.KubitzaM.BeckaW.Mueck. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703-712.
    • (2010) Br J Clin Pharmacol , vol.70 , pp. 703-712
    • Kubitza, D.1    Becka, M.2    Mueck, W.3
  • 32
    • 84964258745 scopus 로고    scopus 로고
    • Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
    • M.ChangZ.YuA.Shenker. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56:637-645.
    • (2016) J Clin Pharmacol , vol.56 , pp. 637-645
    • Chang, M.1    Yu, Z.2    Shenker, A.3
  • 33
    • 84864808150 scopus 로고    scopus 로고
    • Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
    • S.HärtterM.Koenen-BergmannA.Sharma. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74:490-500.
    • (2012) Br J Clin Pharmacol , vol.74 , pp. 490-500
    • Härtter, S.1    Koenen-Bergmann, M.2    Sharma, A.3
  • 34
    • 84877289110 scopus 로고    scopus 로고
    • Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
    • W.MueckD.KubitzaM.BeckaCo-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455-466.
    • (2013) Br J Clin Pharmacol , vol.76 , pp. 455-466
    • Mueck, W.1    Kubitza, D.2    Becka, M.3
  • 35
    • 76749166335 scopus 로고    scopus 로고
    • In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies
    • L.WangD.ZhangN.Raghavan. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448-458.
    • (2010) Drug Metab Dispos , vol.38 , pp. 448-458
    • Wang, L.1    Zhang, D.2    Raghavan, N.3
  • 36
    • 84885129987 scopus 로고    scopus 로고
    • Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
    • J.MendellH.ZahirN.Matsushima. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13:331-342.
    • (2013) Am J Cardiovasc Drugs , vol.13 , pp. 331-342
    • Mendell, J.1    Zahir, H.2    Matsushima, N.3
  • 37
    • 33645779998 scopus 로고    scopus 로고
    • Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
    • D.KubitzaM.BeckaM.ZuehlsdorfW.MueckEffect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549-558.
    • (2006) J Clin Pharmacol , vol.46 , pp. 549-558
    • Kubitza, D.1    Becka, M.2    Zuehlsdorf, M.3    Mueck, W.4
  • 38
    • 84880327613 scopus 로고    scopus 로고
    • Oral apixaban for the treatment of acute venous thromboembolism
    • G.AgnelliH.R.BullerA.Cohen. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.
    • (2013) N Engl J Med , vol.369 , pp. 799-808
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3
  • 39
    • 78650619315 scopus 로고    scopus 로고
    • Oral rivaroxaban for symptomatic venous thromboembolism
    • R.BauersachsS.D.BerkowitzB.Brenner. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.
    • (2010) N Engl J Med , vol.363 , pp. 2499-2510
    • Bauersachs, R.1    Berkowitz, S.D.2    Brenner, B.3
  • 40
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • H.R.BüllerM.H.PrinsA.W.Lensin. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297.
    • (2012) N Engl J Med , vol.366 , pp. 1287-1297
    • Büller, H.R.1    Prins, M.H.2    Lensin, A.W.3
  • 41
    • 84885618705 scopus 로고    scopus 로고
    • Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
    • Hokusai-VTE Investigators; H.R.BüllerH.DécoususM.A.Grosso. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415.
    • (2013) N Engl J Med , vol.369 , pp. 1406-1415
    • Büller, H.R.1    Décousus, H.2    Grosso, M.A.3
  • 42
    • 84894295323 scopus 로고    scopus 로고
    • Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis
    • S.SchulmanA.K.KakkarS.Z.Goldhaber. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-772.
    • (2014) Circulation , vol.129 , pp. 764-772
    • Schulman, S.1    Kakkar, A.K.2    Goldhaber, S.Z.3
  • 43
    • 71849117615 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    • S.SchulmanC.KearonA.K.Kakkar. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
    • (2009) N Engl J Med , vol.361 , pp. 2342-2352
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 44
    • 84866682194 scopus 로고    scopus 로고
    • Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis
    • P.M.ErkensH.ten CateH.R.BullerM.H.PrinsBenchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One. 2012;7:e42269.
    • (2012) PLoS One , vol.7 , pp. e42269
    • Erkens, P.M.1    ten Cate, H.2    Buller, H.R.3    Prins, M.H.4
  • 45
    • 77956232181 scopus 로고    scopus 로고
    • Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes
    • S.B.DeitelzweigJ.LinC.KreilickM.HusseinD.BattlemanWarfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther. 2010;27:623-633.
    • (2010) Adv Ther , vol.27 , pp. 623-633
    • Deitelzweig, S.B.1    Lin, J.2    Kreilick, C.3    Hussein, M.4    Battleman, D.5
  • 46
    • 84884336961 scopus 로고    scopus 로고
    • Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
    • M.H.PrinsA.W.LensingR.Bauersachs. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21.
    • (2013) Thromb J , vol.11 , pp. 21
    • Prins, M.H.1    Lensing, A.W.2    Bauersachs, R.3
  • 47
    • 84874003257 scopus 로고    scopus 로고
    • Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    • S.SchulmanC.KearonA.K.Kakkar. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-718.
    • (2013) N Engl J Med , vol.368 , pp. 709-718
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 48
    • 84873596181 scopus 로고    scopus 로고
    • Apixaban for extended treatment of venous thromboembolism
    • G.AgnelliH.R.BullerA.Cohen. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708.
    • (2013) N Engl J Med , vol.368 , pp. 699-708
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3
  • 49
    • 84966900175 scopus 로고    scopus 로고
    • Antithrombotic therapy for VTE disease: Chest guideline
    • C.KearonE.A.AklJ.Ornelas. Antithrombotic therapy for VTE disease: Chest guideline. Chest. In press.
    • Chest
    • Kearon, C.1    Akl, E.A.2    Ornelas, J.3
  • 50
    • 84931559772 scopus 로고    scopus 로고
    • Overview of the new oral anticoagulants: opportunities and challenges
    • C.H.YehK.HoggJ.I.WeitzOverview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015;35:1056-1065.
    • (2015) Arterioscler Thromb Vasc Biol , vol.35 , pp. 1056-1065
    • Yeh, C.H.1    Hogg, K.2    Weitz, J.I.3
  • 51
    • 84946208087 scopus 로고    scopus 로고
    • Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
    • H.HeidbuchelP.VerhammeM.Alings. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467-1507.
    • (2015) Europace , vol.17 , pp. 1467-1507
    • Heidbuchel, H.1    Verhamme, P.2    Alings, M.3
  • 52
    • 84931567140 scopus 로고    scopus 로고
    • Direct oral anticoagulants (DOACs) in the laboratory: 2015 review
    • D.M.AdcockR.GosselinDirect oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res. 2015;136:7-12.
    • (2015) Thromb Res , vol.136 , pp. 7-12
    • Adcock, D.M.1    Gosselin, R.2
  • 53
    • 84859178003 scopus 로고    scopus 로고
    • How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
    • S.SchulmanM.A.CrowtherHow I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016-3023.
    • (2012) Blood , vol.119 , pp. 3016-3023
    • Schulman, S.1    Crowther, M.A.2
  • 55
    • 84907202540 scopus 로고    scopus 로고
    • Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
    • N.van EsM.CoppensS.SchulmanS.MiddeldorpH.R.BullerDirect oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968-1975.
    • (2014) Blood , vol.124 , pp. 1968-1975
    • van Es, N.1    Coppens, M.2    Schulman, S.3    Middeldorp, S.4    Buller, H.R.5
  • 56
    • 84996497401 scopus 로고    scopus 로고
    • Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review
    • A.Gomez-OutesM.L.Suarez-GeaR.LecumberriA.I.Terleira-FernandezE.Vargas-CastrillonDirect oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag. 2014;10:627-639.
    • (2014) Vasc Health Risk Manag , vol.10 , pp. 627-639
    • Gomez-Outes, A.1    Suarez-Gea, M.L.2    Lecumberri, R.3    Terleira-Fernandez, A.I.4    Vargas-Castrillon, E.5
  • 57
    • 84862894480 scopus 로고    scopus 로고
    • Apixaban: a novel oral inhibitor of factor Xa
    • E.NutescuApixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm. 2012;69:1113-1126.
    • (2012) Am J Health Syst Pharm , vol.69 , pp. 1113-1126
    • Nutescu, E.1
  • 58
    • 84905044202 scopus 로고    scopus 로고
    • Edoxaban: a focused review of its clinical pharmacology
    • G.Y.LipG.AgnelliEdoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014;35:1844-1855.
    • (2014) Eur Heart J , vol.35 , pp. 1844-1855
    • Lip, G.Y.1    Agnelli, G.2
  • 60
    • 84875071896 scopus 로고    scopus 로고
    • Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects
    • S.HärtterR.SennewaldG.NehmizP.ReillyOral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053-1062.
    • (2013) Br J Clin Pharmacol , vol.75 , pp. 1053-1062
    • Härtter, S.1    Sennewald, R.2    Nehmiz, G.3    Reilly, P.4
  • 62
    • 84859032875 scopus 로고    scopus 로고
    • Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study
    • D.KubitzaM.BeckaW.MückS.SchwersEffect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel). 2012;5:279-296.
    • (2012) Pharmaceuticals (Basel) , vol.5 , pp. 279-296
    • Kubitza, D.1    Becka, M.2    Mück, W.3    Schwers, S.4
  • 63
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • M.R.PatelK.W.MahaffeyJ.Garg. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 64
    • 84873569160 scopus 로고    scopus 로고
    • Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    • A.L.DansS.J.ConnollyL.Wallentin. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634-640.
    • (2013) Circulation , vol.127 , pp. 634-640
    • Dans, A.L.1    Connolly, S.J.2    Wallentin, L.3
  • 65
    • 84900992940 scopus 로고    scopus 로고
    • Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes
    • E.M.HylekC.HeldJ.H.Alexander. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141-2147.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2141-2147
    • Hylek, E.M.1    Held, C.2    Alexander, J.H.3
  • 66
    • 84891367149 scopus 로고    scopus 로고
    • Practical management of patients on apixaban: a consensus guide
    • C.WardG.ConnerG.DonnanA.GallusS.McRaePractical management of patients on apixaban: a consensus guide. Thromb J. 2013;11:27.
    • (2013) Thromb J , vol.11 , pp. 27
    • Ward, C.1    Conner, G.2    Donnan, G.3    Gallus, A.4    McRae, S.5
  • 67
    • 84880571372 scopus 로고    scopus 로고
    • Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP): March 2013
    • G.PernodP.AlbaladejoA.Godier. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP): March 2013. Arch Cardiovasc Dis. 2013;106:382-393.
    • (2013) Arch Cardiovasc Dis , vol.106 , pp. 382-393
    • Pernod, G.1    Albaladejo, P.2    Godier, A.3
  • 68
    • 84966965959 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • Boehringer Ingelheim Pharmaceuticals, Inc. Praxbind: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. Accessed February 5, 2016.
    • Praxbind: highlights of prescribing information
  • 69
    • 84879548455 scopus 로고    scopus 로고
    • A specific antidote for dabigatran: functional and structural characterization
    • F.SchieleJ.van RynK.Canada. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554-3562.
    • (2013) Blood , vol.121 , pp. 3554-3562
    • Schiele, F.1    van Ryn, J.2    Canada, K.3
  • 71
    • 84878460192 scopus 로고    scopus 로고
    • A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
    • G.LuF.R.DeGuzmanS.J.Hollenbach. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-451.
    • (2013) Nat Med , vol.19 , pp. 446-451
    • Lu, G.1    DeGuzman, F.R.2    Hollenbach, S.J.3
  • 76
    • 84950127054 scopus 로고    scopus 로고
    • Andexanet alfa for the reversal of Factor Xa inhibitor activity
    • D.M.SiegalJ.T.CurnutteS.J.Connolly. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med. 2015;373:2413-2424.
    • (2015) N Engl J Med , vol.373 , pp. 2413-2424
    • Siegal, D.M.1    Curnutte, J.T.2    Connolly, S.J.3
  • 77
    • 84915821873 scopus 로고    scopus 로고
    • Use of PER977 to reverse the anticoagulant effect of edoxaban
    • J.E.AnsellS.H.BakhruB.E.Laulicht. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141-2142.
    • (2014) N Engl J Med , vol.371 , pp. 2141-2142
    • Ansell, J.E.1    Bakhru, S.H.2    Laulicht, B.E.3
  • 78
    • 84922079881 scopus 로고    scopus 로고
    • New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities
    • P.P.DobeshJ.FanikosNew oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs. 2014;74:2015-2032.
    • (2014) Drugs , vol.74 , pp. 2015-2032
    • Dobesh, P.P.1    Fanikos, J.2
  • 79
    • 84881134435 scopus 로고    scopus 로고
    • Novel direct-acting anticoagulants for risk reduction in ACS
    • P.P.DobeshJ.H.OestreichNovel direct-acting anticoagulants for risk reduction in ACS. J Pharm Pract. 2013;26:358-366.
    • (2013) J Pharm Pract , vol.26 , pp. 358-366
    • Dobesh, P.P.1    Oestreich, J.H.2
  • 80
    • 84925624084 scopus 로고    scopus 로고
    • What is “valvular” atrial fibrillation? A reappraisal
    • R.De CaterinaA.J.Camm. What is “valvular” atrial fibrillation? A reappraisal. Eur Heart J. 2014;35:3328-3335.
    • (2014) Eur Heart J , vol.35 , pp. 3328-3335
    • De Caterina, R.1    Camm, A.J.2
  • 81
    • 84884512133 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with mechanical heart valves
    • J.W.EikelboomS.J.ConnollyM.Brueckmann. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214.
    • (2013) N Engl J Med , vol.369 , pp. 1206-1214
    • Eikelboom, J.W.1    Connolly, S.J.2    Brueckmann, M.3
  • 82
    • 79955432850 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • European Medicines Agency. Pradaxa: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed February 5, 2016.
    • Pradaxa: summary of product characteristics
  • 83
    • 84867577674 scopus 로고    scopus 로고
    • Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis
    • B.I.ErikssonO.E.DahlM.Feuring. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res. 2012;130:818-820.
    • (2012) Thromb Res , vol.130 , pp. 818-820
    • Eriksson, B.I.1    Dahl, O.E.2    Feuring, M.3
  • 84
    • 80055122488 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
    • K.H.LiesenfeldT.LehrC.Dansirikul. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-2175.
    • (2011) J Thromb Haemost , vol.9 , pp. 2168-2175
    • Liesenfeld, K.H.1    Lehr, T.2    Dansirikul, C.3
  • 85
    • 33846448135 scopus 로고    scopus 로고
    • Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
    • D.KubitzaM.BeckaM.ZuehlsdorfW.MueckBody weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218-226.
    • (2007) J Clin Pharmacol , vol.47 , pp. 218-226
    • Kubitza, D.1    Becka, M.2    Zuehlsdorf, M.3    Mueck, W.4
  • 86
    • 84878921385 scopus 로고    scopus 로고
    • Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
    • V.V.UpretiJ.WangY.C.Barrett. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908-916.
    • (2013) Br J Clin Pharmacol , vol.76 , pp. 908-916
    • Upreti, V.V.1    Wang, J.2    Barrett, Y.C.3
  • 88
    • 84882262845 scopus 로고    scopus 로고
    • Disadvantages of VKA and requirements for novel anticoagulants
    • R.ShameemJ.AnsellDisadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103-114.
    • (2013) Best Pract Res Clin Haematol , vol.26 , pp. 103-114
    • Shameem, R.1    Ansell, J.2
  • 89
    • 84927948517 scopus 로고    scopus 로고
    • Site-level variation in and practices associated with dabigatran adherence
    • S.ShoreP.M.HoA.Lambert-Kerzner. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015;313:1443-1450.
    • (2015) JAMA , vol.313 , pp. 1443-1450
    • Shore, S.1    Ho, P.M.2    Lambert-Kerzner, A.3
  • 90
    • 0038718518 scopus 로고    scopus 로고
    • Venous thromboembolism and cancer: risks and outcomes
    • A.Y.LeeM.N.LevineVenous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17-I21.
    • (2003) Circulation , vol.107 , pp. I17-I21
    • Lee, A.Y.1    Levine, M.N.2
  • 91
    • 0037111563 scopus 로고    scopus 로고
    • Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
    • P.PrandoniA.W.LensingA.Piccioli. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
    • (2002) Blood , vol.100 , pp. 3484-3488
    • Prandoni, P.1    Lensing, A.W.2    Piccioli, A.3
  • 92
    • 84923167380 scopus 로고    scopus 로고
    • Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014
    • G.H.LymanK.BohlkeA.A.Khorana. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654-656.
    • (2015) J Clin Oncol , vol.33 , pp. 654-656
    • Lyman, G.H.1    Bohlke, K.2    Khorana, A.A.3
  • 93
    • 84915733549 scopus 로고    scopus 로고
    • Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis
    • M.CarrierC.CameronA.DellucL.CastellucciA.A.KhoranaA.Y.LeeEfficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014;134:1214-1219.
    • (2014) Thromb Res , vol.134 , pp. 1214-1219
    • Carrier, M.1    Cameron, C.2    Delluc, A.3    Castellucci, L.4    Khorana, A.A.5    Lee, A.Y.6
  • 94
    • 84940435041 scopus 로고    scopus 로고
    • Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants
    • F.PoschO.KonigsbruggeC.ZielinskiI.PabingerC.AyTreatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136:582-589.
    • (2015) Thromb Res , vol.136 , pp. 582-589
    • Posch, F.1    Konigsbrugge, O.2    Zielinski, C.3    Pabinger, I.4    Ay, C.5
  • 95
    • 84879575126 scopus 로고    scopus 로고
    • Role of the pharmacist in achieving performance measures to improve the prevention and treatment of venous thromboembolism
    • P.P.DobeshT.C.TrujilloS.W.FinksRole of the pharmacist in achieving performance measures to improve the prevention and treatment of venous thromboembolism. Pharmacotherapy. 2013;33:650-664.
    • (2013) Pharmacotherapy , vol.33 , pp. 650-664
    • Dobesh, P.P.1    Trujillo, T.C.2    Finks, S.W.3
  • 96
    • 3543149439 scopus 로고    scopus 로고
    • Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions
    • C.A.BondC.L.RaehlPharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004;24:953-963.
    • (2004) Pharmacotherapy , vol.24 , pp. 953-963
    • Bond, C.A.1    Raehl, C.L.2
  • 97
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • S.J.ConnollyM.D.EzekowitzS.Yusuf. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 98
    • 77449147211 scopus 로고    scopus 로고
    • Activities of Memphis-area hospitals to meet National Patient Safety Goals for warfarin therapy
    • S.W.FinksC.S.OliphantA.H.Manguso. Activities of Memphis-area hospitals to meet National Patient Safety Goals for warfarin therapy. Am J Health Syst Pharm. 2009;66:2179-2188.
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 2179-2188
    • Finks, S.W.1    Oliphant, C.S.2    Manguso, A.H.3
  • 99
    • 84967071454 scopus 로고    scopus 로고
    • Accessed February 5, 2016
    • Institute for Clinical Systems Improvement. Venous thromboembolism prophylaxis. https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_guidelines/vte_prophy/. Accessed February 5, 2016.
    • Venous thromboembolism prophylaxis
  • 101
    • 84941003169 scopus 로고    scopus 로고
    • Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting
    • J.SimonE.HawesZ.DeyoB.Bryant Shilliday. Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. J Clin Pharm Ther. 2015;40:525-530.
    • (2015) J Clin Pharm Ther , vol.40 , pp. 525-530
    • Simon, J.1    Hawes, E.2    Deyo, Z.3    Bryant Shilliday, B.4
  • 102
    • 84952701083 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
    • X.WangG.TirucheraiT.C.Marbury. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636.
    • (2016) J Clin Pharmacol , vol.56 , pp. 628-636
    • Wang, X.1    Tirucherai, G.2    Marbury, T.C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.